CRUK and Cambridge precision cancer diagnostics spinout Inivata has secured $25m from NeoGenomics as part of a deal that includes an acquisition option.

Cancer diagnostics technology developer Inivata has secured $25m from NeoGenomics to take its total funding to more than $128m.

Naya Capital has returned to reinvest nearly $110m in the Daimler and Didi-backed on-demand ride provider, valuing it just shy of $1.9bn.

Swisscom Ventures has exited invoice financing services provider Advanon in an acquisition of undisclosed size by peer Creditgate24.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The investment bank is establishing a corporate venturing unit that will invest $10m to $20m per deal in financial technology developers.

Illumina and Amgen-backed genomic sequencing technology developer Oxford Nanopore has added $59.6m to a round that now totals $98.1m.

OCD drug developer Exscientia bagged $60m in a Novo-led round that also featured Bristol-Myers Squibb and existing corporate investor Evotec.

Novo has led a $60m series C round for University of Dundee’s Exscientia that also attracted Evotec, Bristol-Myers Squibb, and GT Healthcare Capital.

Oxford Nanopore has added $59.6m to its latest funding round to bring the round to $98.1m and its overall funding to nearly $692m.